Rating Change
Jefferies reiterated its Buy rating on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) on August 17, 2026.
reiterateNASDAQ:EYPT
Jefferies Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Jefferies reiterated its Buy rating on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) on August 17, 2026.
At publication ·
What changed
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) · reiterate
- Firm
- Jefferies
- Rating
- Buy to Buy
- Price at event
- $5.40
- Market capitalization
- $1.1B
At a glance
Key takeaways
- Jefferies reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT) on August 17, 2026, while the stock trades at $5.40 with a market capitalization of $1.1 billion.
Market Context
EyePoint Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $5.40 with a market capitalization of $1.1B. The stock has declined 55.1% over the past 52 weeks.
Analyst coverage from Jefferies provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for EyePoint Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for EyePoint Pharmaceuticals, Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | RBC Capital | Sector Perform | N/A |
| Aug 18, 2026 | Chardan Capital | Neutral | N/A |
| Aug 18, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Aug 17, 2026 | Jefferies | Buy | N/A |
| Aug 17, 2026 | JP Morgan | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View EYPT Stock Page
Frequently Asked Questions
What does the Buy rating mean for EYPT?
A rating of Buy from Jefferies reflects the analyst's outlook on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the EYPT forecast page.